Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 12:39:08 2024-04-29 pm EDT			5-day change	1st Jan Change
1.5 ^CAD	+2.04%		+2.74%	-16.20%

Apr. 11	Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	CI
Apr. 11	Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	MT

Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA

April 11, 2024 at 10:04 am EDT

Oncolytics Biotech Inc. announced the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+ HER2- metastatic breast cancer (mBC). A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment.

The company are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+ HER2- metastatic breast cancer. The company position is strengthened by encouraging data from two randomized studies (BRACELET-1 and IND-213) and the AWARE-1 study, paving the way for the next phase of pelareorep's development and its registration.

Latest news about Oncolytics Biotech Inc.

Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	Apr. 11	CI
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	Apr. 11	MT
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	Apr. 11	MT
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating	Mar. 08	MT
Transcript : Oncolytics Biotech Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain	Mar. 07	MT
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million	Mar. 07	MT
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	Mar. 07	DJ
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	Mar. 05	CI
Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	Mar. 05	MT
Oncolytics Biotech Brief: Says Filed Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	Mar. 05	MT
Oncolytics Biotech Initiating Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 14	MT
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 14	CI
Oncolytics Biotech Brief: Initiating Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 14	MT
Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors	Jan. 09	CI
Oncolytics Biotech Provides Outlook for 2024	Jan. 04	MT
Oncolytics Biotech Brief: Recapping 2023 Accomplishments, Providing Outlook for 2024	Jan. 04	MT
Oncolytics Biotech and SOLTI Present "Positive" Translational Data at SABCS	Dec. 07	MT
Oncolytics Biotech Brief: Oncolytics and SOLTI Present "Positive" Translational Data at SABCS	Dec. 07	MT
HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating	Nov. 13	MT
Oncolytics Says Anal Cancer Cohort Of GOBLET Phase 1/2 Study Meets "Criteria For Efficacy"; Provides Update on Pancreatic Cancer Program	Nov. 09	MT
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep	Nov. 09	MT
Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy	Nov. 09	CI
Oncolytics Biotech Brief: Providing Update on Pancreatic Cancer Program for Pelareorep	Nov. 09	MT

Chart Oncolytics Biotech Inc.

Duration

Period

More charts

Company Profile

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Companyâs primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.47 CAD

Average target price

5.833 CAD

Spread / Average Target

+296.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ONCOLYTICS BIOTECH INC.	-16.20%	80.99M
IQVIA HOLDINGS INC.	+2.62%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.01%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.72%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-22.68%	18.12B
MEDPACE HOLDINGS, INC.	+30.90%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.75%	11.76B
UNITED THERAPEUTICS CORPORATION	+9.55%	11B

Other Biotechnology & Medical Research